Lentivirus Production System Lenti.RiGHT® - Technology

The Lenti.RiGHT^® packaging and producer cell lines are well suited for the reliable and efficient production of lentiviral vectors. Our lentivirus production platform is based on our GMP-grade HEK293 suspension cell, which is stably transfected with all required viral components. The inducible system enables the scalable and efficient production of high-titer lentiviral particles for various applications, starting from early in vitro demonstration testing and preclinical studies and continuing through to gene and cell therapies in a clinical environment.

Ideal use case: Lenti.RiGHT^® is well suited for high-titer viral production for research and early clinical studies.

Flexibility in vector design: Packaging cells without the stable integration of the lentiviral transfer vector allow for quick changes to the transfer vector, making it adaptable for different therapeutic applications.

Streamlined process: This approach simplifies the production process by focusing on the generation of high-titer viral particles without the complications associated with integrating the lentiviral transfer vector into the packaging cell line.

High-titer production: These cells are optimized for high-titer viral production, making them suitable for producing sufficient quantities of vectors for research and early clinical studies.

Ideal use case: Lenti.RiGHT^® is ideally suited for later-phase clinical trials and commercial production.

Consistency and reproducibility: With all lentiviral packaging genes and the transfer vector stably integrated, these production cells ensure consistent vector production, which is critical for clinical applications where batch-to-batch variability must be minimized.

High yield and efficiency: These cells are engineered for optimal expression of all necessary components, leading to high-yield production suitable for the large-scale manufacturing that will be required in later-phase clinical trials and commercial production.

Simplified manufacturing: The stable integration of all components streamlines the manufacturing process, thereby reducing the complexity and variability associated with transient transfections and ensuring a more robust production pipeline. Initial and early material can be provided from clone pool production.

Cost-effectiveness: Over time, the use of these stable production cell lines can be more cost-effective due to reduced variability, elimination of the need for repeated transfections, and consistent high yields, leading to lower overall production costs.